<DOC>
	<DOCNO>NCT00743938</DOCNO>
	<brief_summary>The purpose study improve disease control survival patient treat chemotherapy use BMS-690514 erlotinib</brief_summary>
	<brief_title>A Comparison Between BMS-690514 Erlotinib Patients Who Were Previously Treated NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>ECOG PS 0 1 Histologically confirm NSCLC Adequate amount tumor ( archive fresh ) biomarker evaluation Received one two regimen chemotherapy ( least one platinumcontaining ) Serum creatinine le 1.0 mg/dL 24 hour creatinine clearance great 60 mL/min Stable control blood pressure agent calcium channel blocker Women childbearing potential must avoid pregnancy maintain adequate contraception Must able swallow pill take medication time every day empty stomach ECOG PS 2 great Women unwilling avoid pregnancy use adequate contraception Symptomatic brain metastasis Recent history TIA , CVA , thrombotic/thromboembolic event ( within 6 month ) History hemoptysis great 10 mL/day Significant cardiovascular disease Uncontrolled diarrhea , Crohn 's disease , ulcerative colitis , malabsorptive disease History use TKIs Uncontrolled hypertension HIV+</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>